Atrial flutter medical therapy
Atrial flutter Microchapters
Atrial flutter medical therapy On the Web
American Roentgen Ray Society Images of Atrial flutter medical therapy
Risk calculators and risk factors for Atrial flutter medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. ; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. 
The management of atrial flutter is similar to that of atrial fibrillation with primary goals being control of ventricular rate, restoration of sinus rhythm, and prevention of recurrent episodes and thromboembolic episodes. In the setting of unstable hemodynamics immediate electrical cardioversion is recommended. because of the high success rate and low complication rate radiofrequency ablation is considered superior to medical therapy in atrial flutter.
Treatment goals in the management of atrial flutter include:
- Control of ventricular rate
- Reversion to normal sinus rhythm (NSR)
- Prevention of recurrent episodes and prevention of systemic embolization
Treatment modalities for atrial flutter include:
- Synchronous direct current (DC) cardioversion is used as the initial treatment strategy in the management of hemodynamically unstable atrial flutter patients in the emergency department. External electrical cardioversion is effective in more than 90% of the cases and the initial shock strength used is 50 joules biphasic direct current.
- Sometimes the first shock may convert an atrial flutter to atrial fibrillation, in such cases a second shock preferable of a higher strength is usually given to restore sinus rhythm.
- Electric cardioversion increases the risk of stroke and hence pre-treatment with a blood thinner is advised if time permits.
AV Nodal Agents
- Ventricular rate control is the prime goal in the management of atrial flutter.
- Drugs such as calcium channel blockers (verapamil or diltiazem) or beta-blockers can be used for this. These drugs act as AV node blocking agents and control ventricular rate, thereby preventing tachycardia induced cardiomyopathy.
- Beta-blockers also have a direct antiarrhythmic effect on the atria. Administration of adenosine reveals flutter waves by blocking the AV node.
- History of Wolff-Parkinson-White syndrome or pre-excitation syndrome has to be ruled out before administrating, as these agents while acting on AV node can accelerate conduction in the accessory pathways and can precipitate ventricular fibrillation.
- Digoxin can also be used as an AV blocking agent in combination with calcium channel blockers and beta-blockers in the event of failure of electric cardioversion, atrial pacing and pharmacologic therapy.
- Class III agents like ibutilide, dofetilide, sotalol or amiodarone are typically used for pharmacologic cardioversion in the treatment of atrial flutter.
- Intravenous ibutilide is very effective in controlling acute atrial flutter episodes and is found to be effective in at least 63% of patients.
- Patients who are administered i.v ibutilide should be monitored using an EKG for at least 4 hrs after the infusion as ibutilide is known to cause QT prolongation and torsades de pointes.
- Class IC agents like propafenone or flecainide have also shown to be effective in the conversion of acute onset atrial flutter to normal sinus rhythm.
Rapid Atrial Pacing
- As external electrical cardioversion requires anesthesia some doctors prefer atrial overdrive pacing to terminate episodes of atrial flutter.
- In overdrive pacing the atria are continuously paced at a rate higher than that of the patient's sinus node, which causes an alteration in the atrial rate, propagation and also suppresses the automaticity caused by electrical remodeling in the diseased fibers. Unsuccessful pacing can be due to:
- Insufficient rate and duration of pacing
- Bad electrode contact in the atrium
- Insufficient outlet current
- ↑ Lanzarotti CJ, Olshansky B (November 1997). "Thromboembolism in chronic atrial flutter: is the risk underestimated?". J. Am. Coll. Cardiol. 30 (6): 1506–11. doi:10.1016/s0735-1097(97)00326-4. PMID 9362409.
- ↑ January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC; et al. (2014). "2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society". J Am Coll Cardiol. 64 (21): e1–76. doi:10.1016/j.jacc.2014.03.022. PMID 24685669.
- ↑ Crijns HJ, Van Gelder IC, Tieleman RG, Brügemann J, De Kam PJ, Gosselink AT, Bink-Boelkens MT, Lie KI (January 1997). "Long-term outcome of electrical cardioversion in patients with chronic atrial flutter". Heart. 77 (1): 56–61. doi:10.1136/hrt.77.1.56. PMC 484636. PMID 9038696.
- ↑ Wellens HJ (2002). "Contemporary management of atrial flutter". Circulation. 106 (6): 649–52. doi:10.1161/01.cir.0000027683.00417.9a. PMID 12163422.
- ↑ Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD, Perry KT, Touboul P, Steinbeck G, Wellens HJ (June 1998). "Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group". Heart. 79 (6): 568–75. doi:10.1136/hrt.79.6.568. PMC 1728725. PMID 10078083.
- ↑ Rozsíval V, Kvasnicka J (1984). "Atrial flutter treatment by rapid atrial pacing". Cor Vasa. 26 (3): 167–72. PMID 6478843.